Regado Biosciences Inc 4
4 · Regado Biosciences Inc · Filed Aug 29, 2013
Insider Transaction Report
Form 4
Clark B. Jefferson
Director
Transactions
- Conversion
Common Stock, par value $0.001 per share
2013-08-27+145,411→ 164,722 total(indirect: See Footnote 7) - Conversion
Common Stock, par value $0.001 per share
2013-08-27+133,067→ 385,114 total(indirect: See Footnote 7) - Award
Stock Option (right to buy)
2013-08-27+17,964→ 17,964 totalExercise: $4.00Exp: 2023-08-27→ Common Stock, par value $0.001 per share (17,964 underlying) - Conversion
Series E Preferred Stock
2013-08-27−807,652→ 0 total(indirect: See Footnote 7)→ Common Stock, par value $0.001 per share (48,362 underlying) - Conversion
Common Stock, par value $0.001 per share
2013-08-27+87,325→ 252,047 total(indirect: See Footnote 7) - Conversion
Common Stock, par value $0.001 per share
2013-08-27+321,973→ 707,087 total(indirect: See Footnote 7) - Conversion
Common Stock, par value $0.001 per share
2013-08-27+48,362→ 755,449 total(indirect: See Footnote 7) - Conversion
Series C Preferred Stock
2013-08-27−2,222,222→ 0 total(indirect: See Footnote 7)→ Common Stock, par value $0.001 per share (133,067 underlying) - Conversion
Series D Preferred Stock
2013-08-27+5,376,964→ 0 total(indirect: See Footnote 7)→ Common Stock, par value $0.001 per share (321,973 underlying) - Conversion
Series A Preferred Stock
2013-08-27−2,428,367→ 0 total(indirect: See Footnote 7)→ Common Stock, par value $0.001 per share (145,411 underlying) - Purchase
Common Stock, par value $0.001 per share
2013-08-27$4.00/sh+359,310$1,437,240→ 1,114,759 total(indirect: See Footnote 8) - Conversion
Series B Preferred Stock
2013-08-27−1,458,333→ 0 total(indirect: See Footnote 7)→ Common Stock, par value $0.001 per share (87,325 underlying)
Footnotes (8)
- [F1]100% of the shares underlying the option will vest on the one-year anniversary of the date of grant.
- [F2]The shares of Series A Preferred Stock had no expiration date and automatically converted upon the consummation of the initial public offering of Regado Biosciences, Inc. (the "Company") at a conversion ratio of 1 share of Series A Preferred Stock to 0.05988024 shares of common stock, for no additional consideration.
- [F3]The shares of Series B Preferred Stock had no expiration date and automatically converted upon the consummation of the Company's initial public offering at a conversion ratio of 1 share of Series B Preferred Stock to 0.05988024 shares of common stock, for no additional consideration.
- [F4]The shares of Series C Preferred Stock had no expiration date and automatically converted upon the consummation of the Company's initial public offering at a conversion ratio of 1 share of Series C Preferred Stock to 0.05988024 shares of common stock, for no additional consideration.
- [F5]The shares of Series D Preferred Stock had no expiration date and automatically converted upon the consummation of the Company's initial public offering at a conversion ratio of 1 share of Series D Preferred Stock to 0.05988024 shares of common stock, for no additional consideration.
- [F6]The shares of Series E Preferred Stock had no expiration date and automatically converted upon the consummation of the Company's initial public offering at a conversion ratio of 1 share of Series E Preferred Stock to 0.05988024 shares of common stock, for no additional consideration.
- [F7]Except as noted in footnote 8 of this Form 4, the reportable securities are directly held by Aurora Ventures IV, LLC ("Aurora IV"). The Reporting Person is the manager of A.V. Management IV, L.L.C., the managing member of Aurora IV, and may be deemed to share voting and investment power. The Reporting Person disclaims beneficial ownership of these securities, except to the extent of his pecuniary interest therein, and this report is not an admission that he is the beneficial owner of such securities for purposes of Section 16 or for any other purpose.
- [F8]The reportable securities are directly held by Aurora Ventures V, L.P ("Aurora V"). The Reporting Person is the manager of A.V. Management V, L.L.C., the managing member of Aurora V, and may be deemed to share voting and investment power. The Reporting Person disclaims beneficial ownership of these securities, except to the extent of his pecuniary interest therein, and this report is not an admission that he is the beneficial owner of such securities for purposes of Section 16 or for any other purpose.